Interleukin-8 signalling

Interleukin-8 signalling

IL-8 Overview

Interleukin-8 (IL-8), also known as CXCL8, was discovered over 30 years ago as a small molecule that could promote chemotaxis and induce the production of both superoxide and hydrogen peroxide (H202) (Schroder et al, 1987; Yoshimura et al, 1987). IL-8 is now recognised as a chemokine, which are small chemoattractant molecules that are secreted by cells of the immune system. Chemokines induce integrin expression and primarily attract leukocytes to the site of infection, although their roles have been discovered to be much more diverse (Moser et al, 2013; Constantin et al, 2000). 44 chemokines and 23 chemokine receptors have been identified to date (Nomiyama et al, 2013). Structurally, IL-8 contains two N-terminal cysteine motifs, which classify it as a CXCL family member (Oppenheim et al, 1991). These cysteine motifs are separated by an amino acid which is essential for the specific binding of IL-8 to its membranous receptors CXCR1 and CXCR2 (Herbert et al, 1991). Classification of CXCR1 and CXCR2 determined their expression on several cell types, including endothelial and epithelial cells, as well as fibroblasts and neutrophils (Sturm et al, 2005; Schonbeck et al, 1995). IL-8 is primarily produced by macrophages, epithelial cells, and endothelial cells, and has an important role in cell migration, targeting neutrophils (Klezovitch et al, 2001; Schuerer-Maly, 1994, Bickel, 1993).

IL-8 Signalling

IL-8 can binds to the cell surface receptors CXCR1 and CXCR2, with a greater affinity of IL-8 for CXCR1, with the ligation of IL-8 to CXCR1 induces chemotactic signalling downstream (Hammond et al, 1995). The binding of IL-8 to CXCR1 or CXCR2 triggers a conformational change and leads to the dissociation of cytoplasmic G-coupled protein subunits, Ga and Gbg, facilitating the activation of a variety of signalling pathways, including the mitogen-associated protein kinase (MAPK), phosphatidyl-inositol 3’ kinase/Akt (PI3K/Akt), phospholipase C/protein kinase C (PLC/PKC) pathways (Wu et al, 1993). MAPK signalling leads to the transcription of multiple genes that promote cell proliferation and survival, in addition to pro-inflammatory genes. IL-8 – induced activation of both MAPK and PI3K facilitates the induction of adhesion molecules, such as Mac-1 and integrins, which are critical molecules for mediating chemotaxis (Takami et al, 2002). Furthermore, the production of the second messenger molecule 3,4,5-inositol triphosphate (IP3) leads to the release of intracellular calcium from the endoplasmic reticulum stores, which culminates in the degranulation of neutrophils, a process mediating the release of antimicrobial, cytotoxic molecules (Faurschou and Borregaard, 2003). Overall, IL-8 drives chemotaxis by recruiting neutrophils via a series of complex signalling processes and the secretion of adhesion molecules. Transcription of IL-8 is induced by stimulation with TNFaLPS, IL-1, or by viral infection (Leonard and Toshimura, 1990).

IL-8 in Pathogenesis

It has been long established that elevated levels of IL-8 contribute to the pathogeneses of multiple inflammatory diseases, such as inflammatory bowel disease (Daig et al, 1996; Harada et al, 1996). During chronic inflammatory pathogenesis, increased infiltration of neutrophils concurrent with increased levels of IL-8 is noted. Targeting IL-8 production via the inhibition of NF-kB activation leads to reduce IL-8 transcription in intestinal epithelial cells lead to reduced inflammation in the gastrointestinal tract (Jobin et al, 1998). Moreover, IL-8 induces malignancies, angiogenesis, and cellular invasion. In vitro experiments shave shown that over expression of IL-8 in colon cancer cell lines promotes cell proliferation, angiogenesis and migration (Ning et al, 2011). Recent studies have demonstrated that IL-8 and IL-6 signal synergistically to enhance cellular migration and promotes metastasis, with dual inhibition of both IL-8 and IL-6 leading to a reduced metastatic phenotype in breast cancer (Jayatilaka et al, 2016). High levels of IL-8 has also been associated with poor response to chemotherapy, and downregulating IL-8 levels reduced chemoresistance in hepatocellular carcinoma (Park et al, 2014). Interestingly, CXCR1 and CXCR2 have been identified on immune cells in the CNS; astrocytes and microglia, as well as on neurons (Goczalik et al, 2008; Flynn et al, 2003). Recently, the activation of microglia and astrocytes facilitates the chemokine-induced infiltration of neutrophils into the CNS in response to b-amyloid pathogeneses has been implicated in Alzheimer’s disease pathology (Liu et al, 2014).

Targeting IL-8 as a Therapeutic Strategy

IL-8 inhibition has been explored as a therapeutic target yielding promising results (Schinke et al, 2015). The use of monoclonal antibody to neutralize IL-8 has been demonstrated to reduce the IL-8 – induced detrimental effects in inflammatory pathogeneses (Skov et al, 2008). Targeting the IL-8 receptors is another approach, and notably, it is required that both CXCR1 and CXCR2 are inhibited in order to eliminate the harmful effects of IL-8. Several small molecule inhibitors of CXCR1/CXCR2 have been developed, including repertaxin (Dompé, Italy), SCH479833 (Merck), and SCH527123 (Merck), which have all shown positive anti-tumour results in cases of melanoma, breast cancer and colon cancer (Ning et al, 2012; Genestier et al, 2010; Singh et al, 2009). Due to the pleiotropic nature of many cytokines, including IL-8, it is important to be cautious when developing signalling inhibitors. As IL-8 – induced neutrophil invasion is a homeostatic part of immunosurveillance, the effects of IL-8 inhibitors must be carefully monitored and balanced when developing therapeutics.

Figure 1: IL-8 signalling. IL-8 binds extracellularly to either CXCR1 or CXCR2 at the membrane. This induces a conformational change in the G protein subunits, Gα and Gβγ, which are intracellularly coupled to the CXCR1 and CXCR2 receptors. The conformational change leads to the dissociation of these G protein subunits from the receptor complex activating downstream signalling. The Gα subunit generates cyclic AMP (cAMP) and cAMP which subsequently activate protein kinase A (PKA). The Gβγ subunit activates phospholipids to produce inositol 3,4,5-triphosphate (IP3), which mediates the release of calcium from the endoplasmic reticulum and degranulation, and diacylglycerol (DAG), which signals through PKC to activate MAPK activation.


References:

  1. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol. 1993. 64(5 Suppl):456-60.
  2. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 2000. 13(6):759-69.
  3. Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996. 38(2):216-22.
  4. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003. 5(14):1317-27.
  5. Flynn G, Maru S, Loughlin J, Romero IA, Male D.Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol. 2003. 136(1-2):84-93.
  6. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010. 120(2):485-97.
  7. Goczalik I, Ulbricht E, Hollborn M, Raap M, Uhlmann S, Weick M, Pannicke T, Wiedemann P, Bringmann A, Reichenbach A, Francke M. Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbitretina. Invest Ophthalmol Vis Sci. 2008. 49(10):4578-89.
  8. Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, Giedlin MA, Mullenbach G, Tekamp-Olson P. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995. 155(3):1428-33.
  9. Harada, A., N. Mukaida, and K. Matsushima. Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol. Med. Today. 1996. 2: 482– 489.
  10. Hebert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem. 1991. 266(28):18989–18994.
  11. Jayatilaka H, Tyle P, Chen JJ, Kwak M, Ju J, Kim HJ, Lee JSH, Wu PH, Gilkes DM, Fan R, Wirtz D. Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nat Commun. 2017. 8:15584.
  12. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol. 1998. 160(1):410–418.
  13. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem. 2001. 276(50):46864-9.
  14. Leonard EJ, Yoshimura T. Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). Am J Respir Cell Mol Biol. 1990. 2(6):479-86.
  15. Liu C, Cui G, Zhu M, Kang X, Guo H. Neuroinflammation in Alzheimer’s disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol. 2014. 7(12):8342-55.
  16. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004. 25(2):75-8
  17. Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 2012. 11(6):1353-64.
  18. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011. 128(9):2038-49.
  19. Nomiyama H, Osada N, Yoshie O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells. 2013. 18(1):1-16.
  20. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu Rev Immunol. 1991. 9:617-48.
  21. Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, An SY, Kim JH. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Eur J Cancer. 2014. 50(2):341-50.
  22. Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015. 125(20):3144-52.
  23. Schonbeck U, Brandt E, Petersen F, Flad HD, Loppnow H. IL-8 specifically binds to endothelial but not to smooth muscle cells. J Immunol. 1995. 154(5):2375–2383.
  24. Schroder JM, Mrowietz U, Morita E, Christophers E. Puri cation and partial biochemical characterization of a human monocyte- derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol. 1987;139(10):3474–3483.
  25. Schuerer-Maly CC, Eckmann L, Kagnoff MF, Falco MT, Maly FE. Colonic epithelial cell lines as a source of interleukin 8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994. 81(1):85-91.
  26. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 2009. 15(7):2380-6.
  27. Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, Parren PW, van de Winkel JG. IL8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008. 181(1):669-79.
  28. Sturm A, Baumgart DC, d’Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine. 2005;29(1):42–48.
  29. Takami M, Terry V, Petruzzelli L. Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. J Immunol. 2002. 168(9):4559-66.
  30. Wu D, LaRosa GJ, Simon MI. G protein-coupled signal transduction pathways for interleukin-8. Science. 1993. 261(5117):101-3.
  31. Yoshimura T, Matsushima K, Tanaka S, et al. Puri cation of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987. 84(24):9233–9237.
27th Mar 2020 Sinéad Kinsella PhD

Recent Posts